A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.

"None of the authors has any financial/conflicting interests to disclose."

"Medical writing support was provided by Ann Todd (IMPRINT Science, New York, NY) and was funded by Novartis Pharma AG. This manuscript was developed in accordance with Good Publication Practice (GPP3) guidelines. The authors had full control of the content and made the final decision on all aspects of this publication. Medical writing support was funded by Novartis Pharma AG (Basel, Switzerland). F.G. Holz reports research grants and personal fees from Acucela, Allergan, Apellis Pharmaceuticals, Bayer, Bioeq/Formycon, Chengdu Kanghong Pharmaceutical Group, Geuder, Heidelberg Engineering, IVERIC bio, Novartis, Roche/Genentech, and Zeiss and personal fees from Boehringer Ingelheim, Graybug Vision, Lin BioScience, Pixium Vision, Stealth BioTherapeutics, Aerie, and Oxurion. T. Iida received grants from NIDEK (Japan) and Senju Pharmaceutical (Japan); grants and personal fees from Alcon Pharma (Japan) and Santen Pharmaceutical (Japan); and personal fees from Bayer Yakuhin (Japan). T. Iida also received research support from Canon (Japan), Kowa Pharmaceuticals (Japan), and Topcon (Japan) outside the submitted work. I. Maruko received grants from Japan Society for the Promotion of Science KAKENHI (Grant Number JP20K09781); grants and personal fees from Alcon Pharma; and personal fees from Bayer Yakuhin, Santen Pharmaceutical, Alcon Japan, Topcon, Senju Pharmaceutical, and NIDEK outside the submitted work. S.R. Sadda reports being a consultant for Allergan/AbbVie, Amgen, Apellis Pharmaceuticals, CenterVue, 4D Molecular Therapies, Heidelberg Engineering, IVERIC Bio, Nanoscope Therapeutics, Novartis, Optos, Oxurion, Regeneron Pharmaceuticals, and Roche/Genentech and research instruments from CenterVue, Carl Zeiss Meditec, Heidelberg Engineering, Nidek, Optos, and Topcon."